The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 25, 2016

Filed:

Sep. 13, 2012
Applicants:

Petrus Johannes Simons, Hillegom, NL;

Louis Boon, Badhoevedorp, NL;

Inventors:

Petrus Johannes Simons, Hillegom, NL;

Louis Boon, Badhoevedorp, NL;

Assignees:

Biocerox Products, B.V., Utrecht, NL;

Janssen Pharmaceuticals, Inc., Titusville, NJ (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); G01N 33/68 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2878 (2013.01); G01N 33/6854 (2013.01); C07K 2317/24 (2013.01); C07K 2317/34 (2013.01); C07K 2317/54 (2013.01); C07K 2317/55 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/74 (2013.01); G01N 2333/705 (2013.01);
Abstract

The invention provides antibodies that specifically bind to human CD134. Invention anti-human CD134 antibodies specifically bind to the extracellular domain of human CD134, including non-OX40 ligand (OX40L) binding domains on human CD134, which is expressed on e.g. activated human conventional effector CD4 and/or CD8 T lymphocytes (Teffs) and on activated human suppressive regulatory CD4 T lymphocytes (Tregs). Invention anti-human CD134 antibodies are useful (e.g. to empower Teffs anti-cancer effector function and/or to inhibit Tregs suppressive function) for cancer treatment.


Find Patent Forward Citations

Loading…